Physician_Profile_ID,Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name,Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State,Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID,Total_Amount_of_Payment_USDollars,Date_of_Payment,Form_of_Payment_or_Transfer_of_Value,Record_ID,Name_of_Associated_Covered_Drug_or_Biological1,Name_of_Associated_Covered_Drug_or_Biological2,Name_of_Study,Research_Information_Link,Context_of_Research
806076,"Merck Sharp & Dohme Corporation",NJ,100000000053,547.20,09/13/2013,"In-kind items and services",24490092,MK-3475,"","Randomized, Phase II Study of MK-3475 versus Chemotherapy in Patients with Advanced Melanoma","",""
806076,"Merck Sharp & Dohme Corporation",NJ,100000000053,464.40,12/19/2013,"In-kind items and services",24487569,MK-3475,"","Randomized, Phase II Study of MK-3475 versus Chemotherapy in Patients with Advanced Melanoma","",""
806076,"Merck Sharp & Dohme Corporation",NJ,100000000053,464.40,11/11/2013,"In-kind items and services",24487568,MK-3475,"","Randomized, Phase II Study of MK-3475 versus Chemotherapy in Patients with Advanced Melanoma","",""
806076,"Merck Sharp & Dohme Corporation",NJ,100000000053,309.60,08/13/2013,"In-kind items and services",24490091,MK-3475,"","Randomized, Phase II Study of MK-3475 versus Chemotherapy in Patients with Advanced Melanoma","",""
806076,"Merck Sharp & Dohme Corporation",NJ,100000000053,225.60,08/13/2013,"In-kind items and services",24490089,MK-3475,"","Randomized, Phase II Study of MK-3475 versus Chemotherapy in Patients with Advanced Melanoma","",""
806076,"Merck Sharp & Dohme Corporation",NJ,100000000053,225.60,09/26/2013,"In-kind items and services",24490090,MK-3475,"","Randomized, Phase II Study of MK-3475 versus Chemotherapy in Patients with Advanced Melanoma","",""
806076,"Merck Sharp & Dohme Corporation",NJ,100000000053,182.40,09/26/2013,"In-kind items and services",24490088,MK-3475,"","Randomized, Phase II Study of MK-3475 versus Chemotherapy in Patients with Advanced Melanoma","",""
806076,"Merck Sharp & Dohme Corporation",NJ,100000000053,154.80,09/26/2013,"In-kind items and services",24490087,MK-3475,"","Randomized, Phase II Study of MK-3475 versus Chemotherapy in Patients with Advanced Melanoma","",""
806076,"Merck Sharp & Dohme Corporation",NJ,100000000053,112.80,09/26/2013,"In-kind items and services",24490048,MK-3475,"","Randomized, Phase II Study of MK-3475 versus Chemotherapy in Patients with Advanced Melanoma","",""
